Defining Safety Beyond Adverse Events in Chronic Skin Disease

A panelist discusses how favorable safety profiles of novel oral systemics, comparable to placebo in trials, may influence clinician confidence, especially for patients with multiple comorbidities. They highlight the importance of interpreting these results cautiously in real-world settings, where older and more complex patient populations may face higher risks.

A panelist discusses how generating evidence in difficult-to-treat areas such as the scalp, nails, and genitals is vital to improving quality of life and holistic patient outcomes. They stress that dermatologists must balance efficacy and safety while considering broader clinical contexts, including surgical interventions that may overlap with systemic therapy use.

A panelist discusses how withdrawal and re-treatment data, though valuable, only partially reflect real-world complexity, emphasizing the need for long-term safety end points and real-world data collection. These insights, they note, will be key to refining confidence in oral systemic therapies and guiding more nuanced patient management strategies moving forward.